The anti-apoptotic function of human αA-crystallin is directly related to its chaperone activity

N Pasupuleti1, S Matsuyama2, O Voss3,4, AI Doseff3,4, K Song2, D Danielpour2 and RH Nagaraj*,1

αA-crystallin is a molecular chaperone and an antiapoptotic protein. This study investigated the mechanism of inhibition of apoptosis by human αA-crystallin and determined if the chaperone activity of αA-crystallin is required for the antiapoptotic function. αA-crystallin inhibited chemical-induced apoptosis in Chinese hamster ovary (CHO) cells and HeLa cells by inhibiting activation of caspase-3 and -9. In CHO cells, it inhibited apoptosis induced by the overexpression of human proapoptotic proteins, Bim and Bax. αA-crystallin inhibited doxorubicin-mediated activation of human procaspase-3 in CHO cells and it activated the PI3K/Akt cell survival pathway by promoting the phosphorylation of PDK1, Akt and phosphatase tensin homologue in HeLa cells. The phosphoinositide 3 kinase (PI3K) activity was increased by αA-crystallin overexpression but the protein content was unaltered. Downregulation of PI3K by the expression of a dominant-negative mutant or inhibition by LY294002 abrogated the ability of αA-crystallin to phosphorylate Akt. These antiapoptotic functions of αA-crystallin were enhanced in a mutant protein (R21A) that shows increased chaperone activity than the wild-type (Wt) protein. Interestingly, a mutant protein (R49A) that shows decreased chaperone activity was far weaker than the Wt protein in its antiapoptotic functions. Together, our study results show that αA-crystallin inhibits apoptosis by enhancing PI3K activity and inactivating phosphatase tensin homologue and that the antiapoptotic function is directly related to its chaperone activity.

Cell Death and Disease (2010) 1, e31; doi:10.1038/cddis.2010.3; published online 18 March 2010

Subject Category: Experimental Medicine

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.

α-Crystallin is a major structural protein of the lens; it accounts for nearly 40% of the total protein in the lens and is required for maintenance of lens transparency. The lens grows throughout age, though at a very slow rate. The proteins in the lens have negligible turnover and therefore their levels remain more or less constant during aging. α-Crystallin consists of two similar subunits, αA- and αB-crystallin, that exist in the lens as heteroaggregates in a 3:1 ratio with an average molecular mass of ~800 kDa. Human αA- and αB-crystallin share nearly 60% sequence homology. Although αA-crystallin is expressed mainly in the lens and shows low levels of expression in the retina, αB-crystallin is expressed at high levels in the lens and in other tissues, such as skeletal and cardiac muscle, kidney and brain.

α-Crystallin belongs to the small heat shock protein (sHSP) superfamily, featured by a conserved crystallin domain flanked by an N-terminal and a short C-terminal domain. sHSPs, including α-crystallin, are antiapoptotic proteins that provide protection against a wide range of cellular stresses. It has been reported that cells overexpressing αA- or αB-crystallin are more resistant to thermal, osmotic and oxidative stress. In addition, recent studies have shown that α-crystallin prevents apoptosis induced by a variety of agents, including staurosporine, tumor necrosis factor-α, UVA light, hydrogen peroxide and etoposide. The robust effects of α-crystallin against these apoptosis inducers prompted many researchers to investigate molecular mechanisms by which α-crystallin functions as an antiapoptotic protein. α-Crystallin has been shown to bind the pro-apoptotic molecules p53, Bax and Bcl-X(S), and therefore could prevent their translocation to mitochondria during apoptosis. It has been shown that αB-crystallin can suppress autocatalytic maturation of procaspase-3 and inhibit cytochrome c release during apoptosis. Whether αA-crystallin shows these properties is not yet known. During fiber cell differentiation in the lens, α-crystallin suppresses caspase activity, resulting in the retention of lens fiber cell integrity following degradation of mitochondria and other organelles.
organelles. This finding suggests that αA-crystallin might possess antiapoptotic functions similar to αB-crystallin. UVA-induced apoptosis in lens epithelial cells is inhibited by αA- and αB-crystallins through regulation of PKC-ζ, RAF/MEK/ERK and Akt signaling pathways, suggesting additional mechanisms of apoptosis inhibition. Phosphorylation of α-crystallin appears to be important for its antiapoptotic function, as mimicking phosphorylation of αB-crystallin at serine-59 appears to be sufficient to protect cardiac myocytes from apoptosis. Whether this property applies for αA-crystallin is not known.

In addition to being antiapoptotic proteins, both αA- and αB-crystallins are molecular chaperones; they prevent aggregation of structurally perturbed proteins. It has been reported that, under heat and other stress conditions, proteins retain their native secondary structure in the presence of α-crystallin. A decrease in the chaperone function of α-crystallin in the aging lens may be one reason for the onset of age-related cataracts in humans.

Although glycation, a posttranslational modification of proteins by sugars and ascorbate, reduces the chaperone function of α-crystallin, modification of α-crystallin by a similar process initiated by methylglyoxal (MGO) improves its chaperone function. MGO is a metabolic product derived from glycolytic intermediates and is present ubiquitously in humans and in relatively large amounts in the human lens. Reaction of MGO with αA-crystallin produces argpyrimidine and hydromidazolone adducts on arginine residues in tissue proteins, including proteins of the lens. We previously identified argpyrimidine on R21, R49 and R103 in MGO-modified αA-crystallin. Later, we used site-directed mutagenesis in which specific arginine residues were replaced with alanines and showed that the R21A and R103A mutations made αA-crystallin a better chaperone, whereas the R49A mutation made it a weaker chaperone. The double mutant R21A/R49A was a better chaperone compared with the unmodified protein, which implied that R21A mutation overrode the negative effect of R49A mutation. These studies showed that chemical modification by MGO may be beneficial to the chaperone function of αA-crystallin in the lens.

The R116C and R49C mutations in human αA-crystallin and R120G and P20S mutations in αB-crystallin, which are associated with autosomal dominant cataracts in humans, cause weaker chaperone function along with considerably lower antiapoptotic functions relative to the wild-type (WT) protein. Despite these advances in our understanding of αA-crystallin’s chaperone and antiapoptotic functions, it is not clear whether the two are directly linked. In this study, we show by several criteria that these functions are intimately coupled.

Results

Overexpression of human αA-crystallin. We generated stable cell lines in Chinese hamster ovary (CHO) cells that overexpressed WT, R21A or R49A. Clones expressing human αA-crystallin were analyzed by western blot analysis using an anti-αA-crystallin antibody (Figure 1a). Purified human αA-crystallin of varied concentrations was used to quantify the expression of human αA-crystallin. Positive clones expressing comparable amounts of human αA-crystallin, ~2.5 ng human αA-crystallin per mg of total protein, were used. WT, R21A or R49A were also overexpressed in HeLa cells by transient transfections (Figure 1b). Our data suggest that the two cell types expressed similar levels of each αA-crystallin variant.

R21A mutant protein is a better chaperone in CHO cells. To determine if overexpressed αA-crystallin shows chaperone function in CHO cells and if R21A and R49A mutant show their expected changes in the chaperone function, we used a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) aggregation assay. We first determined the optimal temperature and time for complete aggregation of GAPDH and found that incubation at 55°C for 3 h resulted in...
complete aggregation of the pure protein. On the basis of this result, we incubated cell lysates at 55°C for 3 h and then fractioned the lysate into soluble and insoluble fractions followed by western blotting for GAPDH. We found that in all cell lysates not subjected to heat treatment, GAPDH was entirely present in the supernatant fraction (Figure 1c). However, in heat-treated cell lysates GAPDH was found in the pellet fraction as well. In the lysate of cells with empty vector (EV), GAPDH was present entirely in the pellet fraction and in the lysate of cells with Wt protein, it was present both in the soluble and insoluble fractions, suggesting Wt protein inhibited aggregation of GAPDH. In the lysate of cells expressing R21A protein, GAPDH was mostly present in the supernatant fraction, but it was entirely present in the pellet fraction in the lysate from cells expressing R49A protein. These data imply that the overexpressed R21A mutant protein is a better chaperone and R49A is a weak chaperone relative to Wt protein in CHO cells.

R21A mutant protein is a better antiapoptotic protein. We have previously shown that the R21A mutation in human αA-crystallin increases its chaperone function, whereas the R49A mutation decreases this function.29 To determine whether these changes in chaperone function translate into a gain or loss of antiapoptotic function, we measured apoptosis in CHO cell lines incubated with apoptosis-inducing chemicals, staurosporine or etoposide. In dimethyl sulfoxide (DMSO)-treated cells, no apoptosis was observed (data not shown). In EV-transfected cells, ~52% cells were apoptotic on staurosporine treatment. This percentage increased to ~60% in the case of R49A mutant protein-overexpressing cells. Apoptosis was inhibited by R21A mutant protein overexpression, and the number of apoptotic cells was 38%, which was 14% lower than EV-transfected cells (Figure 2a). Similar results were observed when apoptosis was induced by 10 μM etoposide. Although cells overexpressing R21A showed nearly 33% reduction in apoptotic cells, cells overexpressing R49A showed a 22% increase in apoptotic cells when compared with EV-transfected cells (Figure 2b). Similar results were obtained in transiently transfected HeLa cells; R21A was better and R49A was worse than Wt in preventing apoptosis induced by either staurosporine (Figure 2c) or etoposide (Figure 2d). These results indicate that R21A has enhanced and R49A has reduced antiapoptotic activity, relative to Wt protein, and that the gain or loss of antiapoptotic function coincides with the chaperone function of αA-crystallin.

Bax translocation to mitochondria is better inhibited by R21A. Bax is activated and translocated from the cytosol into mitochondria during apoptosis. Because it has been shown that αA-crystallin directly interacts with Bax,9 we reasoned that such an interaction could affect translocation of Bax into mitochondria during apoptosis and that the R21A mutation may affect this function. To test this hypothesis, we transiently overexpressed green fluorescent protein (GFP)-human Bax in CHO cells (stably transfected with αA-crystallin). Expression of GFP-Bax was confirmed by western blot analysis (Figure 3a). Cells were fractionated into cytosolic and membrane fractions. Mitochondria were found

---

**Figure 2** R21A provides better protection against apoptosis. Apoptosis was induced in αA-crystallin overexpressing Chinese hamster ovary (CHO) cells and HeLa cells by either 100 nM staurosporine or 10 μM etoposide. CHO cells were grown to 100% confluency and then treated with 100 nM staurosporine (a) or 10 μM etoposide (b) in 0.01% dimethyl sulfoxide (DMSO) for 36 h. Similarly HeLa cells were treated with either 100 nM staurosporine (c) or 10 μM etoposide (d) for 24 h. Cells were treated with Hoechst stain to estimate the percentages of apoptotic cells. Bars that do not share a common superscript are statistically significant at P<0.0001. In each case, n = 3.
to be enriched in the membrane fraction. In cells overexpressing Wt, Bax was seen in both the cytosolic and membrane fractions (Figure 3b). By contrast, in R21A-overexpressing cells, most of Bax was present in the membrane fraction. Remarkably, in R49A-overexpressing cells, most of Bax was present in the membrane fraction.

GFP-Bax expression induced apoptosis in CHO cells; nearly 90% of the cells were apoptotic in GFP-Bax (no αA-crystallin) cells. This percentage was reduced by about 50% in GFP-Bax/αA-crystallin (Wt) cells and further reduced by 35% in GFP-Bax/αA-crystallin (R21A) cells. In contrast, apoptosis increased and reached 90% in GFP-Bax/αA-crystallin (R49A) cells (Figure 3c). Taken together, these results suggest that R21A is better and R49A is worse than Wt in preventing Bax translocation to mitochondria and inhibiting Bax-mediated apoptosis.

**R21A provides better protection against Bim-induced apoptosis.** Bim is a BH3-only member of the Bcl2 family that functions as a death signal sensor.33 We tested whether R21A mutant protein is able to prevent Bim-induced apoptosis better than the Wt protein by transient transfection of human Bim into CHO cells. Western blot analysis for Bim showed similar levels of expression in all cell lines (Figure 3d). Similar to Bax overexpression, Bim overexpression caused apoptosis in CHO cells. We observed nearly 90% of Bim (no αA-crystallin) cells to be apoptotic; however, apoptosis decreased to 58 and 43% in Bim/αA-crystallin (Wt) and Bim/αA-crystallin (R21A) cells, respectively (Figure 3e). In contrast, nearly 90% of the Bim/αA-crystallin (R49A) cells were apoptotic. Thus, R21A mutant protein was better than Wt protein against Bim-induced apoptosis, and this protection ability was compromised in R49A mutant protein.

**R21A offers better protection against cytochrome c release from mitochondria.** Exposure of cells to high temperatures causes activation of Bax and subsequent release of cytochrome c from mitochondria.34 We investigated whether αA-crystallin could inhibit or prevent such an effect and whether R21A mutant protein performs that function better than Wt protein. CHO cells were incubated at 43°C for 1 h, followed by incubation at 37°C for another hour.
Cells were fractionated into cytosolic and membrane (contains mitochondria) fractions as described above. Western blotting for cytochrome c in the two fractions showed that, in R21A mutant protein-overexpressing cells, cytochrome c was mostly present in the membrane fraction (Figure 3f), whereas it was mostly present in the cytosolic fraction in R49A mutant protein-overexpressing cells. Cytochrome c was observed in the cytosolic fraction of cells transfected with EV, as expected. Cells expressing Wt protein showed nearly equal quantities of cytochrome c in the two fractions. These data further strengthen our notion that R21A mutant protein is a better antiapoptotic agent and that R49A mutant protein is a weaker antiapoptotic relative to Wt.

Caspases are less active in R21A mutant protein-overexpressing cells. Previous studies have shown that translocation of Bax from the cytosol to mitochondria induces the release of cytochrome c from mitochondria and thereby leads to activation of caspases. Because R21A mutant protein-overexpressing cells sequestered most of Bax in the cytosol, we tested whether expression of R21A mutant protein had an effect on the activity of caspases. Apoptosis in CHO cell lines was induced by treatment with 100 nM staurosporine in DMSO. Cells treated with DMSO alone served as a control. We measured caspase-3 and -9 activities in cell lysates using their respective fluorogenic peptide substrates. In Wt cells, caspase-3 and -9 activities were nearly 30 and 20% lower, respectively, when compared with cells transfected with the EV (Figure 4a and b). Cells expressing R21A mutant protein had further reduced activities, by 52 and 50%, respectively. In contrast, activities of both caspases were elevated in cells overexpressing R49A and were comparable to those observed in cells transfected with vector alone.

Doxorubicin-induced apoptosis in procaspase-3-overexpressing cells is significantly inhibited by R21A. αB-crystallin inhibits caspase-8-mediated maturation of procaspase-3 to active caspase-3. We sought to determine whether the reduced activity of caspase-3 in CHO cell lines (above) is due to αA-crystallin’s ability to inhibit maturation of procaspase-3, similar to αB-crystallin. To accomplish this goal, we overexpressed human procaspase-3 in CHO cell lines and in untransfected CHO cells, which also allowed us to investigate whether R21A mutant protein is a better inhibitor of procaspase-3 maturation, mirroring its other antiapoptotic properties. Western blotting confirmed overexpression of procaspase-3 in all cell lines except in untransfected cells; procaspase-3 overexpression did not result in its autocatalytic maturation (data not shown). When cells were treated with 20 μM doxorubicin for 12 h, a clear increase in cleaved caspase-3 was observed. Caspase-3 activation was inhibited by R21A mutant protein and to a
lesser extent by Wt protein; however, R49A mutant protein was unable to inhibit caspase-3 activation (Figure 4c). We then evaluated caspase-3 activity in cells; procaspase-3 overexpression alone did not cause an increase in caspase-3 activity, but doxorubicin treatment resulted in massive induction of the enzyme (Figure 4d). Although R21A mutant protein overexpression significantly reduced caspase-3 activity, R49A overexpression was ineffective at reducing the activity. Wt protein inhibited caspase-3 activity, although this effect was lower than that of R21A mutant protein. These results suggest that αA-crystallin inhibits maturation of procaspase-3 and further confirm that R21A mutant protein is better than Wt protein, and that R49A mutant form is a relatively poor inhibitor of procaspase-3 activation.

**Enhanced antiapoptotic function of R21A mutant protein is due to its higher ability to activate PI3K.** Akt is phosphorylated by phosphoinositide 3 kinase (PI3K). Hsp27, a related heat shock protein, has been shown to inhibit apoptosis by activating Akt through PI3K. Our studies on the role of αA-crystallin PI3K signaling pathway initially used CHO cells. However, we realized that many of the commercial antibodies to signaling proteins of the PI3K pathway did not work in CHO cells and therefore we used HeLa cells in our subsequent experiments. To determine if αA-crystallin’s ability to inhibit apoptosis was due to its effect on PI3K, we measured the PI3K activity in HeLa cells overexpressing Wt and mutant proteins. We found that cells overexpressing R21A had the higher PI3K activity (~25% higher) than cells overexpressing Wt protein (Figure 5a). Cells overexpressing R49A had activity comparable to cells transfected with the EV. These data suggest that higher PI3K activity in R21A cells is responsible for its better antiapoptotic function.
We then determined if the increased PI3K activity in R21A cells was due to higher expression of the protein by western blotting using an antibody to p110α, the catalytic subunit of PI3K. We found no difference in PI3K protein level in cells overexpressing Wt or the mutant proteins (Figure 5b). Thus, it appears that R21A activates PI3K better than the Wt protein and this ability is lost in R49A.

To confirm whether PI3K is involved in α-A-crystallin-mediated inhibition of apoptosis, we incubated cells with a PI3K inhibitor, LY294002. Cells were incubated with or without 20 μM LY294002 for 2 h followed by treatment or nontreatment with 100 nM staurosporine. LY294002 treatment alone increased apoptosis in untransfected cells; these effects were further enhanced in staurosporine-treated cells (Figure 5c). In CHO cell lines, treatment with LY294002 completely abolished the antiapoptotic function of Wt protein. Interestingly, even in R21A cells, the apoptotic rate was similar to that of the Wt cells. R49A showed responses similar to those of the Wt and R21A cells. These results suggest that PI3K activity is required for the antiapoptotic function of α-A-crystallin.

To further confirm the involvement of PI3K, we transduced our cell lines with dominant-negative PI3K or empty adenovirus to block the activity of PI3K specifically. Cells were then treated with staurosporine to induce apoptosis. The dominant-negative vector has been shown to inhibit PI3K robustly.37 We confirmed this effect by measuring Akt phosphorylation at serine 473 using western blot analysis. It was completely blocked by expression of the dominant-negative mutant (Figure 5d), but was unaffected in cells transduced with EV. Expression of the dominant-negative mutant alone caused apoptosis (Figure 5e); this effect was exaggerated by staurosporine treatment. In all cell lines, expression of the dominant-negative mutant resulted in a failure to protect against staurosporine-induced apoptosis; however, transduction of the empty adenovirus vector did not change the gain or loss of antiapoptotic function in R21A and R49A. These results suggest that α-A-crystallin inhibits apoptosis through activation of PI3K.

Phosphorylation of Akt, PDK1 and PTEN is elevated by R21A. The above results suggested that PI3K adenovirus inhibits the intrinsic pathway of apoptosis through activation of the PI3K-mediated signaling pathway. It is well established that PI3K-mediated activation Akt promotes cell survival.38 It has been shown that human α-A-crystallin activates the Akt survival pathway to counteract UVA-induced apoptosis.17 Therefore, we investigated the downstream signaling of the PI3K pathway.

Phosphatidylinositol(3,4,5)-triphosphate (PI(3,4,5)P₃) produced from PI3K activity recruits Akt to the plasma membrane. At the plasma membrane, Akt is phosphorylated at Thr308 and Ser473 by PDK1 and PDK2, respectively.34,39 We analyzed Akt phosphorylation in CHO cell lines after treatment with 100 nM staurosporine for 3 h. Robust Akt phosphorylation (at Ser473) was observed in R21A mutant protein-overexpressing cells (data not shown), but this response was muted in Wt protein-overexpressing cells and was completely absent in both R49A protein-overexpressing cells and in cells transduced with the EV. Experiments on HeLa cells allowed us to determine if phosphorylation occurs on Thr308 as well, as commercial antibodies to Thr308 phosphorylation did not work with CHO cells. In 100 nM staurosporine-treated HeLa cells, Akt phosphorylation at both Thr308 and Ser473 was elevated in R21A-overexpressing cells than in cells overexpressing Wt protein, but such phosphorylation was completely absent in R49A-overexpressing cells and in EV-transfected cells (Figure 6a).

One of the upstream kinases that activates Akt is PDK1.46 We investigated if α-A-crystallin activates Akt through activation of PDK1. In HeLa cells treated with 100 nM staurosporine, we found PDK1 to be phosphorylated at Ser241 in R21A-expressing cells (Figure 6b). This response, although seen with cells overexpressing Wt protein, was less apparent. However, PDK1 phosphorylation was not seen in either R49A protein-overexpressing cells or in cells transduced with the EV.

Next we studied the phosphorylation status of phosphatase tensin homologue (PTEN) in HeLa cells. PTEN is a dual lipid and protein phosphatase. PTEN dephosphorylates PI(3,4)P and PI(3,4,5)P acting as an antagonist of PI3K effects. It is known that phosphorylation of PTEN at the C-terminal tail suppresses the activity of PTEN.40 We found increased phosphorylation of PTEN in R21A-overexpressing cells when compared with cells overexpressing Wt (Figure 6c). R49A overexpressing cells and cells with EV did not show PTEN phosphorylation. Together these results show that the increased ability of R21A protein to protect cells from apoptosis is due to reduced PTEN activity, thus further promoting activation of Akt through PDK1 phosphorylation.

Discussion
The purpose of this study was twofold: (1) to determine if the antiapoptotic function of α-A-crystallin is related to its chaperone function and (2) to evaluate whether argpyrimidine-modifiable arginine residues that enhance or reduce the chaperone function dictate the antiapoptotic function. We have previously shown that MGO, a metabolic dicarbonyl compound, reacts with Hsp27 and makes it a better antiapoptotic protein.41 We also showed that MGO reacts with specific arginine residues in α-A-crystallin and converts them to argpyrimidine.24 We have found that such conversion at R21 makes α-A-crystallin a better chaperone and conversion at R49 makes it a poor chaperone. We then showed that removal of the positive charge by substitution with alanine at these sites had the same effect on protein function as argpyrimidine modification.29 The finding that the chaperone function could be modulated by point mutations of specific arginine residues enabled us to undertake this study. The principal findings of this study are that the enhanced chaperone function of α-A-crystallin strictly correlates with enhanced protection against the intrinsic apoptosis pathway and that loss of chaperone function has the opposite effect. The improvement in antiapoptotic function occurred through (1) increased PI3K activity and enhanced Akt phosphorylation by PDK1, (2) increased phosphorylation of PTEN, (3) increased inhibition of Bax translocation to mitochondria and Bim-mediated apoptosis, (4) decreased cytochrome c release from mitochondria and (5) increased inhibition of caspase-9.
activity followed by inhibition of caspase-3 activation. These data clearly suggest that the chaperone function is directly related and possibly essential for the antiapoptotic function of αA-crystallin.

Bcl2 family proteins control mitochondrial outer membrane permeabilization (MOMP). Activation of Bax and/or Bak is required for MOMP; however, mechanisms by which Bax and Bak become activated are still being studied. The direct activation model suggests that BH3-only proteins, such as, Bim and tBid, can bind directly to Bax and Bak and promote their activation. The indirect activation model suggests that Bim binds to antiapoptotic Bcl2 proteins and displaces Bax, which subsequently results in Bax activation. According to the first model, interaction with Bim results in structural perturbation at the N- and C termini of Bax, which then translocates to mitochondria, oligomerizes on the mitochondrial outer membrane and causes MOMP. We showed that overexpression of R21A is able to inhibit Bax translocation. This finding suggests that R21A could interfere with Bim binding to Bax, or that it might interact directly with structurally perturbed Bax through its chaperone property, thereby blocking its translocation and oligomerization on the mitochondrial outer membrane. Along these lines, it has been shown that heat treatment in a cell-free system induces

**Figure 6**  R21A induces Akt, PDK1 and phosphatase tensin homologue (PTEN) phosphorylation. HeLa cells overexpressing human Wt, R21A or R49A αA-crystallin were treated with 100 nM staurosporine or 0.01% dimethyl sulfoxide (DMSO) for 12 h. Cell lysates (100 μg of protein each) were subjected to western blot analysis. (a) pAkt levels at Thr308 and Ser473 using an anti-pAkt (Thr308) and anti-pAkt (Ser473) polyclonal antibodies, respectively. Total Akt was detected using an anti-Akt polyclonal antibody. (b) Detection of pPDK1 and total PDK1 using an anti-pPDK1 (Ser241) and anti-PDK1 polyclonal antibodies, respectively. (c) Detection of pPTEN (Ser380/Thr382/383) and total PTEN using an anti-pPTEN polyclonal and an anti-PTEN polyclonal antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. (d) A conceptual mechanism by which αA-crystallin inhibits apoptosis by the PI3K/PDK1/Akt pathway: αA-crystallin enhances the PI3K activity and decreases PTEN activity through phosphorylation (dashed line) leading to increased production and retention of phosphatidylinositol(3,4,5)-triphosphate (PI(3,4,5)P3). This favors recruitment of Akt to the plasma membrane allowing its phosphorylation at Thr308 and Ser473 by PDK1/2. Activated Akt then detaches from the membrane and inactivates Bax by phosphorylation. Inactive Bax is unable to translocate to mitochondria, which prevents cytochrome c release into the cytoplasm. The ensuing inhibition of caspase activation leads to inhibition of apoptosis.
oligomerization and activation of Bax and 2A-crystallin has been shown to bind thermally destabilized proteins. Thus, it is possible that 2A-crystallin can bind to structurally perturbed Bax during its activation by Bim.

When we overexpressed Bim in CHO cells, it induced spontaneous apoptosis, as expected. The R21A mutant was effective, unlike R49A mutant, at inhibiting such apoptosis. This finding suggests that R21A interacts directly with and sequesters Bim or that it binds to Bax and prevents Bim-mediated activation of Bax. Further studies are needed to test these possibilities.

The lower activity of caspase-3 in R21A cells relative to R49A cells could be because of either a direct interaction of 2A-crystallin with procaspase-3 or indirect effects through inhibition of Bax translocation to mitochondria. The former possibility is supported by observations that 2B-crystallin and Hsp27, two proteins related to 2A-crystallin, interact directly with procaspase-3 and inhibit its activation. During apoptosis, caspase-9 activates procaspase-3 through apoptosisome formation. It is likely that 2A-crystallin, similar to Hsp27, might bind to the propeptide and inhibit the maturation process. Work is underway to investigate this possibility.

There seems to be another level, either Bax-independent or -dependent, at which 2A-crystallin inhibits apoptosis. PI3K leads to stimulation of PI-dependent kinase through PI(3,4,5)P3, which increases Akt phosphorylation and, subsequently, activity of Akt. We found that the PI3K activity was elevated in R21A cells when compared with Wt cells and was diminished in R49A cells. However, we did not observe any significant difference in the expression level of PI3K. Exactly how 2A-crystallin activates PI3K is uncertain at this time, but our data point to the possibility that it could do so by enhancing the phosphorylation of PI3K. Our study data show that when PI3K is inhibited either by LY294002 or by a dominant-negative mutation, the antiapoptotic function of 2A-crystallin, including that of the R21A mutant, is completely abolished. These observations imply that PI3K/Akt pathway activation is involved in 2A-crystallin’s antiapoptotic function.

A previous study showed that 2A-crystallin activates Akt by phosphorylation at Ser473. Our study showed that in addition to Ser473, 2A-crystallin promotes phosphorylation at Thr308 and that R21A is better than Wt in promotion of phosphorylation at these two sites. Our study also showed that 2A-crystallin-mediated Thr308 phosphorylation is due to an increase in phosphorylation of PKD1 (at Ser241). The promotion of Akt phosphorylation by R21A could lead to inhibition of Bax translocation to mitochondria, as phosphorylated Akt has been shown to induce Bax phosphorylation, which leads to its sequestration and heterodimerization with the antiapoptotic Bcl2 family members, Mcl-1 and Bcl-xL.

We cannot rule out other mechanisms by which Akt phosphorylation could inhibit apoptosis, such as phosphorylation and inhibition of proapoptotic mediators, such as Bad and caspase-9. On the basis of our results, we propose that 2A-crystallin functions as an antiapoptotic protein by increasing PI3K activity and decreasing the PTEN activity (Figure 6d).

We believe that the findings of this study significantly impact on our understanding of the role of 2A-crystallin in diseases. In the human lens the chaperone function of 2A-crystallin decreases during aging and cataract formation. On the basis of the results in this study, we believe that such a decrease in the chaperone function could reduce its antiapoptotic function as well. Whether 2A-crystallin content decreases in the epithelial cells of cataractous lenses is not clear, but if it does, it could render lens epithelial cells more susceptible to apoptosis. In fact, in human and experimental cataracts, lens epithelial cell apoptosis has been observed. Although such apoptosis is not extensive, it may be sufficient to cause damage to the lens. Lens epithelial cells synthesize high amounts of 2A-crystallin. Whether expression protects epithelial cells from apoptosis in vivo should be investigated. Previous work using 2A-crystallin knockout animals suggests that lens epithelial cells become genomically unstable and undergo enhanced apoptosis in the absence of 2A-crystallin. A recent study showed that differentiated fiber cells undergo apoptosis in the absence of 2A-crystallin in the mouse lens.

The antiapoptotic function of 2A-crystallin may also be important in other tissues. In the ischemic heart, phosphorylated 2B-crystallin is translocated to mitochondria where it stabilizes mitochondrial membrane potential and inhibits apoptosis. 2A-crystallin has been shown to protect cancer cells from apoptosis in glioblastoma and retinoblastoma. A recent study showed that 2B-crystallin is an oncoprotein that is highly expressed in breast carcinomas and its expression independently predicts survival in this disease. 2A-crystallin appears to be important for the prevention of apoptosis in vascular cells as well. Our previous study using human umbilical vein endothelial cells showed that hyperglycemia-induced apoptosis can be inhibited by overexpression of 2B-crystallin. In addition, we have previously shown that apoptosis of retinal capillary pericytes, which is associated with a decrease in 2B-crystallin content, can be prevented by the overexpression of 2B-crystallin. A recent report shows that 2B-crystallin promotes tumor angiogenesis by increasing endothelial cell survival during tube morphogenesis. Thus, it is apparent that 2A- and 2B-crystallins are important in the prevention of apoptosis in many different tissues.

In summary, we have shown in this study that the antiapoptotic property of 2A-crystallin is directly related to its chaperone function. The fact that modification of R21 to argpyrimidine by a metabolic dicarbonyl MGO had similar effects on the chaperone function of 2A-crystallin, combined with the present finding that the R21A mutant protein is superior to Wt protein in terms of antiapoptotic functions, suggests that low cellular concentrations of MGO may help cells to cope with stress by preventing protein aggregation and apoptosis.

Materials and Methods
Cloning. Wt 2A-crystallin cDNA was excised from pCMS-EGFP plasmid using NheI and XbaI and inserted into pcDNA 3.1(−) vector. R21A cDNA was generated by PCR using forward primer 5′-CTGAGAATTCATGGACGTGACCTCCAGCAC-3′ and reverse primer 5′-CCGCAGGAGGCTCGACCGAGG-3′ and the R21A-pET23d plasmid as template. The PCR product was then inserted into pCDNA3.1(−) vector between EcoRI and HindIII restriction sites. R49A cDNA was amplified using the R49A-pET23d plasmid as template by PCR using the above primers and cloned with the same restriction sites as described for R21A.
Cell culture. Chinese hamster ovary cells (Invitrogen, Carlsbad, CA, USA) and HeLa cells were used for the study. Cells were transfected with either empty pcDNA3.1(−) vector or vector coding for WR, R21A or R49A α-crystallin. Transient transfections were performed in HeLa cells using SuperFect transfection reagent. HeLa cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. CHO cells were used to establish stable cell lines expressing α-crystallin using Lipofectamine, according to the manufacturer’s instructions (Invitrogen). Cells were cultured in Ham’s F12 media supplemented with 10% fetal bovine serum. Transfected cells were then selected by treatment with 4G18 (400 μg/ml). Colonies were isolated and individual colonies were expanded. Each colony was derived from a single cell. Cells lysates were prepared from 1 × 10^6 cells using mammalian protein extraction reagent (MPER) reagent (Pierce, Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s protocol. The expression of α-crystallin in CHO cell lines was analyzed by western blot using an α-crystallin polyclonal antibody (Assay Designs, Ann Arbor, MI, USA). The expression levels of α-crystallin in CHO cell lines were calculated by comparison with densitometric values obtained from varied concentrations of purified human α-crystallin. Monoclonal mouse antiGAPDH antibody (Chemicon International, Temecula, CA, USA) was used to detect GAPDH, which served as a loading control.

GAPDH aggregation assay. Stable cell lines were grown to 100% confluence in Ham’s F12 media containing 10% fetal bovine serum. CHO cells were used to establish stable cell lines expressing human α-crystallin in CHO cell lines were calculated by comparison with densitometric values obtained from varied concentrations of purified human α-crystallin. Monoclonal mouse antiGAPDH antibody (Chemicon International, Temecula, CA, USA) was used to detect GAPDH, which served as a loading control.

Transient transfection of CHO cell lines with human GFP-Bax, BimEL and procaspase-3. GFP-Bax and Bim, both in pcDNA3.1(−) vector (Shigemi Matsuyama), were transiently transfected into CHO cell lines (each 7 × 10^4 cells) using SuperFect transfection reagent (Qiagen, Valencia, CA, USA). To generate full-length caspase-3-FLAG (FL-caspase-3-FLAG), we amplified pQE31 plasmid containing the human caspase-3 cDNA using the forward primer 5′-GGATTCGGAATTC GCCACCATGTCTGGAATATCC-3′ and reverse primer 5′-A-CTCTGAGTGTCGACGCGTGATAAAAATAGAG-3′. The DNA was cloned into the BamH1 and SalI sites of the mammalian pcCMV-(4B)-FLAG expression vector (Staragene, La Jolla, CA, USA) generating the C-terminal FLAG epitope-tagged caspase-3. FL-caspase-3-FLAG clones were confirmed by sequencing and protein expression using the anti-Flag antibody (Clone M2; Sigma). Procaspase-3 in pcMV vector (Assay Designs) was transiently transfected as described above. In these experiments, cells transfected with or without EV served as controls. The expression of the proteins in transfected cells was confirmed by western blotting (see below).

Western blot analysis. Cell lysis was performed for Bax, Bim by incubation in a cell lysis buffer obtained from Cell Signaling (Danvers, MA, USA; catalog no. 9803) as per the manufacturer’s instructions. Cell lysis for procaspase-3 was performed as previously reported.55 Cell lysis were passed through a 26-gauge needle several times in the presence of 1 mM phenylmethylsulfonyl fluoride and 5 μl/mi protease inhibitor cocktail (Sigma; catalog no. P8340). Protein concentration was determined using the Bio-Rad protein assay kit with bovine serum albumin as the standard. Samples corresponding to 50–100 μg protein were electroblotted onto a 15% SDS-PAGE gel and then transferred onto a nitrocellulose membrane for 80 min at 100 V. Nonspecific binding was blocked by incubation with 5% non-fat dry milk in Tris-buffered saline-Tween 20 buffer for 1 h at room temperature. The membrane was then incubated with one of the following primary antibodies: α-crystallin (polyclonal; Assay Designs), Bax, procaspase-3, pAkt (Ser473), pAkt (Thr308), Akt, pPDK1 (Ser241), PDK1, pPTEN (Ser380/Thr382/383), PTEN, p110α (all polyclonal; Cell Signaling), BimEL (polyclonal; Calbiochem, San Diego, CA, USA), cytochrome c (monoclonal; Assay Designs), at 1: 1000 dilution overnight at 4°C. A monoclonal antibody for GAPDH was added at a 1:10,000 dilution and incubated overnight at 4°C. HRP-conjugated goat anti-rabbit or goat anti-mouse secondary antibody was used at a 1: 5000 dilution for 1 h at room temperature. Immunoreactivity was detected using SuperSignal West Pico chemiluminescence substrate (Pierce).

Cell fractionation. Subcellular fractionation to determine Bax translocation was performed using the Qproteome Cell Compartment Kit (Qiagen). Mitochondrial and cytosolic fractions were separated according to the manufacturer’s instructions. Manganese superoxide dismutase (MnSOD; mitochondrial marker protein) was detected using an anti-MnSOD polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cytosolic marker protein GAPDH was detected by anti-GAPDH antibody.

Induction of apoptosis. Stable cell lines were grown to 100% confluence in Ham’s F12 media containing 10% fetal bovine serum in the presence of 400 μg/ml G418. Cells were then plated in media containing 0.1% DMISO (control) or DMSO containing 100 nM staurosporine or 10 μM etoposide for 24–36 h or 20 μM doxorubicin for 12 h. After treatment, all samples were collected and analyzed for apoptosis. The percentage of apoptotic and viable cells was measured by Hoechst staining. A total of 300 cells were counted. The percentage of apoptotic cells and viable cells relative to the total number of cells was calculated.

Caspase-3 and -9 activities. Cells were collected and lysed as described above. Cell lysates were incubated in a black microwell plate for 2 h at 37°C with 50 μl of either 50 mM DEVD-APC in 10% glycerol, 50 mM 1,4-piperazinediethane-sulfonic acid (pH 7.0), 1 mM EDTA, 1 mM dithiothreitol to measure caspase-3 activity or 50 mM LEHD-APC in the same buffer to measure caspase-9 activity. Samples were read at 400/505 nm excitation/emission wavelengths using a Spectramax Gemini XS 4 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).

PI3K activity assay. The activity of PI3K was determined using the PI3K activity ELISA Kit (Echelon Biosciences, Salt Lake City, UT, USA). HeLa cells were transiently transfected with either EV or vector harboring WR, R21A and R49A mutant of human α-crystallin for 24 h. Cells were treated with 100 nM staurosporine for 16 h. Cell lysis was used for immunoprecipitation of PI3K using an anti-PI3K antibody (Upstate Biotechnology, Temecula, CA, USA) and a competitive ELISA was used to measure PI3K activity following the manufacturer’s protocol.

Blocking of PI3K activity in CHO cell lines. For inhibition of PI3K activity, CHO cells were grown to 100% confluence in Ham’s F12 media and incubated with or without 20 μM LY294002 for 2 h. Cells without the inhibitor served as the control. Following the treatment, cells were incubated with or without 100 nM staurosporine for 36 h. Cells were stained with Hoechst stain to measure apoptosis as described above. To block PI3K activity in cells, we transduced cells with an adenovirus harboring a dominant negative form of PI3K (PI3K DN-PI3K),57 CHO cell lines were plated overnight at a density of 1 × 10^5 cells per 2 ml in Ham’s F12 media in 6- or 12-well plates and were then infected overnight with 2.5 × 10^9 PFU per ml with either an empty adenovirus or adenovirus carrying DN-PI3K. The transduction efficiency was previously established to be greater than 95%.57 Cells were washed once with PBS, and were then cultured for an additional 24 h in 2 ml of Ham’s F12 medium containing 100 nM staurosporine.

Statistics. Data are expressed as mean ± S.D. Statistical significance among groups was analyzed by ANOVA followed by the Fisher’s least significant difference test. P < 0.05 was considered statistically significant.

Conflict of interest. The authors declare no conflict of interest.

Acknowledgements. This study was supported by NIH Grants R01EY-016219, R01EY-09812 (RH), P01EY11373 (Visual Sciences Research Center of CWRU), R01CA102074 (DD), R01HL075040 (SM), R01CA107304 (AID), R01AG031903 (SM), by a Senior Scientific Investigator Award from Research to Prevent Blindness foundation of New York to RHN and by the Ohio Lions Eye Research Foundation.

1. Bloemendal H. Links proteins. CRC Crit Rev Biochem 1982; 12: 1–38.
2. van der Ouderaa FJ, de Jong WW, Bloemendal H. The amino-acid sequence of the alpha(A) chain of bovine lens crystallin. J Mol Biol 1973; 80: 267–282.
3. Srinivasan AN, Nagineni CN, Bhat SP. alpha A-crystallin is expressed in non-ocular tissues. J Biol Chem 1992; 267: 23337–23341.
4. de Jong WW, Leunissen JA, Voorter CE. Evolution of the alpha-crystallin/small heat-shock protein family. Mol Biol Evol 1993; 10: 103–128.
5. Aoyama A, Frohli E, Schafer R, Klemenz R. Alpha B-crystallin expression in mouse NIH 3T3 fibroblasts: glucocorticoid responsiveness and involvement in thermal protection. Mol Cell Biol 1993; 13: 1824–1835.

6. Dasgupta S, Hohnan TC, Carper D. Hypertonic stress induces alpha B-crystallin expression. J Biol Chem 1992; 267: 461–470.

7. Andley UP, Patel HC, Xi JM. The H116C mutation in alpha A-crystallin diminishes its protective ability against stress-induced lens epithelial cell apoptosis. J Biol Chem 2002; 277: 10178–10186.

8. Andley UP, Song Z, Wawrousek EF, Fleming TP, Bassnett S. Differential protective activity of alpha A- and alphaB-crystallin in lens epithelial cells. J Biol Chem 2000; 275: 36823–36831.

9. Mao YW, Liu JP, Xiang H, Li DW. Human alphaA- and alphaB-crystallins bind to Bax and Bcl-2(X) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ 2004; 11: 526–536.

10. Nakanishi P, Schubert-Drost K, Arigo AP. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/ apoptosis-1- and staurosporine-induced cell death. J Biol Chem 1996; 271: 1650–16514.

11. Mao XW, Green GM, Gridley DS. Evaluation of polyasparticacid receptors against C6 glioma in combination with radiation. Oncology 2001; 6: 243–253.

12. Liu S, Li J, Tao Y, Xiao X. Small heat shock protein alphaB-crystallin binds to p53 to regulate apoptosis. FEBS Lett 2002; 525: 38–42.

13. Kamradt MC, Chen F, Sam S, Cryns VL. The small heat shock protein alpha B-crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 2006; 103: 923–928.

14. Horwitz J. Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 1996; 93: 1997–2002.

15. Kamradt MC, Chen F, Sam S, Cryns VL. The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 2002; 277: 37631–37636.

16. Kamradt MC, Chen F, Sam S, Cryns VL. The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its apoptotic autoregulation. J Biol Chem 2001; 276: 16095–16098.

17. Liu JP, Schlosser R, Ma WY, Dong Z, Feng H, Liu L. Alpha A- and alphaB-crystallin prevent UV-induced apoptosis through regulation of PKCalpha, RAF/MEK/ERK and AKT signaling pathways. Exp Eye Res 2004; 79: 393–403.

18. Morrison LE, Hoover HE, Therueau DJ, Glimbert CS. Mimicking phosphorylation of alphaA-crystallin on serine-59 is necessary and sufficient to provide maximal protection of myofibrils against in vitro browning on alpha-crystallin chaperone-like activity: physiological significance and caveats. J Biol Chem 2005; 280: 243–250.

19. Horwitz J. Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 1999; 96: 10444–10449.

20. Bicemendal H, de Jong W, Jaenicke R, Lubsen NH, Slingsby C, Tardieu A. Ageing and vision: the role of small heat shock proteins. Vision Res 2003; 43: 203–211.

21. Bloemendal H, de Jong W, Jaenicke R, Lubsen NH, Slingsby C, Tardieu A. Ageing and vision: the role of small heat shock proteins. Vision Res 2003; 43: 203–211.

22. Derham BK, Harding JJ. Effect of aging on the chaperone-like function of human alphaA-crystallin. Vision Res 2004; 44: 1737–1746.

23. Derham BK, Harding JJ. Effect of aging on the chaperone-like function of human alphaA-crystallin. Vision Res 2004; 44: 1737–1746.

24. Horwitz J. Alpha-crystallin. Exp Eye Res 2003; 76: 145–153.

25. Weber A, Paschen SA, Heger K, Wilfing F, Frankenberger T, Bauerschmidt H et al. Bim-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 2007; 177: 625–636.

26. Voss OH, Batra S, Kolattukudy SJ, Gonzalez-Mejia ME, Smith JB, Doejeit AL. Binding of caspase-3–protein to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J Biol Chem 2007; 282: 25088–25099.

27. Lu JP, Schlosser R, Ma WY, Dong Z, Feng H, Liu L. et al. Human alphaA- and alphaB-crystallins prevent UVA-induced apoptosis through regulation of PKCalpha, RAF/MEK/ERK and AKT signalling pathways. Exp Eye Res 2004; 79: 393–403.

28. Gardali SJ, Hildeman DA, Francliek SK, Whitcock BB, Frasch SC, Brogaard N et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. Circ Res 2003; 92: 525–530.

29. Lailier L, Carton PF, Jun P, Nedekina S, Manon S, Becherger B et al. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007; 12: 887–896.

30. Pagliar L, Kumana T, Bonz, Nweidy DM, Tu S, Beere HM et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc Natl Acad Sci USA 2005; 102: 17973–17980.

31. Hopiwitz J. Alpha-crystallin. Exp Eye Res 2003; 76: 145–153.

32. Weber A, Paschen SA, Heger K, Wilfing F, Frankenberger T, Bauerschmidt H et al. Bim-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 2007; 177: 625–636.

33. Voss OH, Batra S, Kolattukudy SJ, Gonzalez-Mejia ME, Smith JB, Doejeit AL. Binding of caspase-3–protein to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J Biol Chem 2007; 282: 25088–25099.

34. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB et al. Methylglyoxal modification and phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. Cell Death and Disease 2011; 2: 195–211.

35. Andley UP. The lens epithelium: focus on the expression and function of the alpha-crystallin chaperones. J Biol Chem 2008; 40: 517–522.

36. Whittaker R, Glassy MS, Gude N, Susman MA, Gottlieb RA, Glimbert CS. Kinetics of the transcription and phosphorylation of (alpha)B-crystallin in mouse heart mitochondria during ex vivo ischemia. Am J Physiol Heart Circ Physiol 2009; 296: H1663–H1642.

37. Siegel AH, Kesari S, Mahoney JE, Jenq HT, Fortonley KL, Propopov A et al. Bcl-2-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008; 105: 10703–10708.

38. Kase S, Park JH, Rao NA. Expression of alpha-crystallin in retinoblastoma. Arch Ophthalmol 2009; 127: 187–192.

39. Moonay JV, Evans JR, Chen FL, Li M, Werner ME, Yealhy F et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2008; 118: 261–270.

40. Nagarahar Y, Oya-Ito T, Bhat M, Liu B. Dicarbonyl stress and apoptosis of vascular cells: prevention by alphaB-crystallin. Ann N Y Acad Sci 2005; 1043: 158–165.

41. Erus L, Bhat M, Padival AK, Smith DG, Nagarahar RH. Effect of dicarbonyl modification of fibrinogen on retinal capillary pericytes. Invest Ophthalmol Vis Sci 2004; 45: 1983–1985.
64. Dimberg A, Rylova S, Dieterich LC, Olsson AK, Schiller P, Wikner C et al. alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood 2008; 111: 2015–2023.

65. Hayes VH, Devlin G, Quinlan RA. Truncation of alphaB-crystallin by the myopathy-causing Q151X mutation significantly destabilizes the protein leading to aggregate formation in transfected cells. J Biol Chem 2008; 283: 10500–10512.

66. Voss OH, Kim S, Wewers MD, Doseff AI. Regulation of monocyte apoptosis by the protein kinase Cdelta-dependent phosphorylation of caspase-3. J Biol Chem 2005; 280: 17371–17379.

67. Song K, Cornelius SC, Reiss M, Danielpour D. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 2003; 278: 38342–38351.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/